A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon‐alpha2
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5285
Abstract: Conventional cytoreductive therapy for patients with chronic Philadelphia‐negative myeloproliferative neoplasms (MPNs) includes hydroxyurea (HU), interferon‐alpha2 (IFN), and anagrelide. HU is worldwide the most used cytoreductive agent, which lowers elevated blood cell counts within days in… read more here.
Keywords: cell counts; cell; hydroxyurea interferon; interferon alpha2 ... See more keywords
Second malignancies in hydroxyurea and interferon‐treated Philadelphia‐negative myeloproliferative neoplasms
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Haematology"
DOI: 10.1111/ejh.12787
Abstract: In an era of controversy in regard to ‘hydroxyurea‐leukaemogenicity’ and when interferon‐alfa2 (IFN) is being revived in the treatment of Philadelphia‐negative myeloproliferative neoplasms (MPNs), we aim in this single‐centre observational study to describe the frequencies… read more here.
Keywords: second malignancies; philadelphia negative; negative myeloproliferative; hydroxyurea interferon ... See more keywords